Could a common arthritis drug prevent preterm birth?
NCT ID NCT05703425
First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This study tests whether sulfasalazine, a drug used for arthritis, can lower a stress hormone called CRH and prevent recurrent preterm birth. Fifty pregnant women with a history of preterm birth will receive either sulfasalazine or no drug between 24 and 36 weeks of pregnancy. Researchers will track CRH levels and how many deliver early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sulfasalazine
- What this could lead to
- If it works, this could offer a new way to prevent preterm birth in women who have had one before.
- What could go wrong
- This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. The drug may not lower CRH levels or reduce preterm birth rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRETERM BIRTH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rutgers Robert Wood Johnson Medical School
RECRUITINGNew Brunswick, New Jersey, 08901, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a toddler supplement shape brain power years later?
- Teaching Moms-to-Be about seafood safety: a new weapon against toxic exposures?
- Can Early-Life factors steer preterm and term infant health?
- Immune clues in pregnancy: a new test for preterm birth risk?
- Online support may help mothers of preterm infants breastfeed and care with confidence
- Gum inflammation in pregnancy linked to preterm birth risk?